The colorectal cancer treatment market could reach $5.03 billion by 2021, growing at a compound annual growth rate of 2.21 percent from 2016 to 2021, according to Market Data Forecast analysis.
Here's what you should know:
1. Analysts believe the market is limited by a lack of neoadjuvant/adjuvant pipeline agents. However, they also believe that inefficiency creates an area lush for drug developers to step into and grow.
2. If new agents aren't developed, analysts believe the drug-facing market could experience a period of status quo.
3. The North American market holds the largest market share, and analysts are still projecting considerable growth. However, high screening cost could hinder market growth.
4. These companies are highly active in the North American market:
- Abbott Diagnostics
- Alere
- Beckman Coulter
- Clinical Genomics
- Companion Dx
- Hoffmann La Roche
- Debiopharm Group
- Vaccinogen BD
More articles on gastroenterology:
GI center to know: Spokane Digestive Disease Center
Solutions for every setting — Gastroenterologist Dr. Michael DiMarino on the gMed™ suite
GI leader to know: Dr. Paul Craig of Valley Gastroenterology
l